Feng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Feng Wang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Aggrey Dhabangi
Child Health and Development Centre Makerere University College of Health Sciences Kampala Uganda
1 shared publication - Charles Musoke
Makerere University College of Health Sciences, Kampala, Uganda
1 shared publication - Christine Cserti‐Gazdewich
Department of Laboratory Medicine and Pathobiology University of Toronto Toronto Ontario Canada
1 shared publication - Dylan Kain
Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada
1 shared publication - Hani Kim
Sandra A Rotman Laboratory, McLaughlin-Rotman Centre for Global Health, University Health Network/University of Toronto, Toronto, ON, Canada
1 shared publication - Katharine Xing
Sandra A Rotman Laboratory, McLaughlin-Rotman Centre for Global Health, University Health Network/University of Toronto, Toronto, ON, Canada
1 shared publication
Latest Publications
- Open Access
- 19 March 2013
- Published by Springer Nature in Malaria Journal
- Vol. 12 (1) , 105
Systemic release of high mobility group box 1 (HMGB1) protein is associated with severe and fatal Plasmodium falciparum malaria
Background: Severe falciparum malaria (SM) pathogenesis has been attributed, in part, to deleterious systemic host inflammatory responses to infection. High mobility group box 1 (HMGB1) protein is an important mediator of inflammation implicated in sepsis pathophysiology.Methods: Plasma levels of HMGB1 were quantified in a cohort of febrile Ugandan children withPlasmodium falciparuminfection, enrolled in a prospective observational case-controlled study, using a commercial enzyme-linked immunosorbent assay. The utility of HMGB1 to distinguish severe malaria (SM; n = 70) from uncomplicated malaria (UM; n = 33) patients and fatal (n = 21)versusnon-fatal (n = 82) malaria, at presentation, was examined. Receiver operating characteristic curve analysis was used to assess the prognostic accuracy of HMGB1. The ability ofP. falciparum-parasitized erythrocytes to induce HMGB1 from peripheral blood mononuclear cells was assessedin vitro. The effect of an anti-HMGB1 neutralizing antibody on disease outcome was assessed in the experimentalPlasmodium bergheiANKA rodent parasite model of SM. Mortality and parasitaemia was assessed daily and compared to isotype antibody-treated controls.Results: Elevated plasma HMGB1 levels at presentation were significantly associated with SM and a subsequent fatal outcome in paediatric patients withP. falciparuminfection.In vitro, parasitized erythrocytes induced HMGB1 release from human peripheral blood mononuclear cells. Antibody-mediated neutralization of HMGB1 in the experimental murine model of severe malaria failed to reduce mortality.Conclusion: These data suggest that elevated HMGB1 is an informative prognostic marker of disease severity in human SM, but do not support HMGB1 as a viable target for therapeutic intervention in experimental murine SM.
- 19 March 2013
- Published by Springer Nature in Malaria Journal
- Vol. 12 (1) , 105
Open AccessSystemic release of high mobility group box 1 (HMGB1) protein is associated with severe and fatal Plasmodium falciparum malaria
Background: Severe falciparum malaria (SM) pathogenesis has been attributed, in part, to deleterious systemic host inflammatory responses to infection. High mobility group box 1 (HMGB1) protein is an important mediator of inflammation implicated in sepsis pathophysiology.Methods: Plasma levels of HMGB1 were quantified in a cohort of febrile Ugandan children withPlasmodium falciparuminfection, enrolled in a prospective observational case-controlled study, using a commercial enzyme-linked immunosorbent assay. The utility of HMGB1 to distinguish severe malaria (SM; n = 70) from uncomplicated malaria (UM; n = 33) patients and fatal (n = 21)versusnon-fatal (n = 82) malaria, at presentation, was examined. Receiver operating characteristic curve analysis was used to assess the prognostic accuracy of HMGB1. The ability ofP. falciparum-parasitized erythrocytes to induce HMGB1 from peripheral blood mononuclear cells was assessedin vitro. The effect of an anti-HMGB1 neutralizing antibody on disease outcome was assessed in the experimentalPlasmodium bergheiANKA rodent parasite model of SM. Mortality and parasitaemia was assessed daily and compared to isotype antibody-treated controls.Results: Elevated plasma HMGB1 levels at presentation were significantly associated with SM and a subsequent fatal outcome in paediatric patients withP. falciparuminfection.In vitro, parasitized erythrocytes induced HMGB1 release from human peripheral blood mononuclear cells. Antibody-mediated neutralization of HMGB1 in the experimental murine model of severe malaria failed to reduce mortality.Conclusion: These data suggest that elevated HMGB1 is an informative prognostic marker of disease severity in human SM, but do not support HMGB1 as a viable target for therapeutic intervention in experimental murine SM.